Abstract
SummaryAsparaginase, injected in conventional therapeutic doses into mice previously inoculated with the lactate dehydrogenase-elevating virus (LDH-virus), disappeared from the peripheral blood at a significantly slower rate than in corresponding virus-free mice. Direct testing of the transplanted tumors and leukemias employed in the earlier studies on the antitumor properties of asparaginase have indicated that the virus, was unknowingly present. The evidence indicates that the virus, through its impairment of host enzyme clearance and possibly other factors, played a significant role in the observed therapeutic effects of EC-2 l-asparaginase against sensitive mouse leukemia and lymphosarcoma.We thank J. D. Loveless, M. A. Fitzmaurice, and Edith R. Shapiro for assistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
